News & Updates
Showing Obstetrics & Gynaecology articles
Showing
Show Multimedia Only

Fulvestrant-palbociclib combo pre-progression improves PFS in ESR1+ mBC
12 Jan 2022
byRoshini Claire Anthony
Switching to a fulvestrant-palbociclib regimen prior to disease progression after detection of elevated ESR1 mutations in the blood of patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) who were receiving aromatase inhibitors (AIs) plus palbociclib extended their progression-free survival (PFS), results of the phase III PADA-1 trial showed.
12 Jan 2022

Pyrotinib + capecitabine extends OS in metastatic breast cancer
10 Jan 2022
byRoshini Claire Anthony
Patients with previously treated HER2-positive metastatic breast cancer (mBC) experienced a 31 percent reduced risk of death when treated with pyrotinib plus capecitabine than lapatinib plus capecitabine, according to updated results of the phase III PHOEBE trial from China.
10 Jan 2022






